Market Research Blog – Page 14935 – New Product Development

Physical Therapy Supplies Market is likely to boost the growth in the coming years

Physical Therapy Supplies Market Overview

As per The Institute of Physical Therapy and Applied Science, physical therapy is a holistic approach based on the manual treatment of soft tissues, i.e. muscles, tendons, ligaments and fascia. Hence, physical therapy differs greatly from physiotherapy as it does not specially treat the spine. The main equipment used for physical therapy include ramps, exercise balls, resistance exercise bands, Nordic Track, treatment tables, ultrasound, Isokinetic devices, electrical muscle stimulation equipment, etc. The global physical therapy supplies market is likely to witness sustained growth in the next 10 years.

Physical Therapy Supplies Market: Drivers

In countries such as United States, there is a huge growth in the demand for physical therapy and this field is exhibiting a dynamic expansion in variety of new areas such as eldercare and sports medicine. As per the figures released by the World Health Organization, till 2014, 13% of the total world population was suffering from obesity. This has a direct impact on the number of people needing physical therapy and hence the physical therapy supplies market is expanding. This is likely to boost the growth of the physical therapy supplies market in the coming years.

In addition, there is a noticeable increase in the number of disabled people in the world and they are likely to develop chronic conditions. Also, the baby boomer generation is now getting old and they are likely to suffer from ailments such as heart diseases and stroke. Hence, the demand of physical therapists treating this segment of population is also increasing and this has a positive effect on the physical therapy supplies market. The other major contributing factor in the increasing demand for the physical therapy supplies market is the rise in unhealthy lifestyle habits.

Physical Therapy Supplies Market: Segmentation

The physical therapy supplies market is classified into physical therapy services, occupational therapy services, respiratory therapy services and other kind of therapies. Amongst these, the physical therapy services market is the largest market, as such kind of services are being increasingly used by the elderly population to counter the ill effects of illnesses such as arthritis and osteoporosis.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2241

Physical Therapy Supplies Market: Key Market Players

The largest 50 competitors in the global physical therapy supplies market comprise less than 25% of the global physical therapy supplies market. The reason for this is that the physical therapy supplies market is largely comprised of small independent practices rather than one consolidated entity.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, types and applications.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain

Regional analysis includes:

North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain)
Eastern Europe (Poland, Russia)
Asia Pacific (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

For critical insights, request for PDF Brochure https://www.futuremarketinsights.com/reports/brochure/rep-gb-2241

About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Stretcher Accessories Market Revenue Growth Predicted by 2026

Stretcher Accessories Market Overview

A stretcher is a device used for moving patients who require some kind of medical care or assistance and are unable to walk themselves for any reason. They are used by hospitals and nursing homes primarily. There are several types of stretchers like cots and litters which are carried by two people or wheeled ones known as gurneys, trolleys or beds. The stretcher accessories market includes everything which aid the medical staff to assist the patient like different kinds of incubators, cot handles to bend the cot over when at its lowest position, poles to keep the stretcher upright and mattresses to make the patient comfortable while also minimizing their movement while transporting. There is a recent trend to rent out slings or lifts for a short duration to patients (typically 4 to 6 months) along with flexible rent payment options which enable hospitals to easily manage their cash flows year round. This would also be expected to drive the demand for the stretcher accessories market forward.

Stretcher Accessories market Drivers

An increasing number of disabilities, accidents mainly in the developing world, an aging population in the developed world, high risk of injury to medical staff while aiding patients and strict regulations against manually lifting heavy loads can all be expected to grow both the stretcher and the stretcher accessories market in the medium to long term. According to World Health Organization data, the global scourge of disease is expected to involve 1.18 million patients per year by 2021 and nearly 1.43 by 2031. A study conducted by the Occupational Safety and Health Administration (OSHA) observed that musculoskeletal problems like strains and sprains were one of the main causes of injury to health care workers and these happened while manually moving, shifting and or lifting patients. Hence, they are adopting wheeled stretchers to assist them which would also increase the scope of the stretcher accessories market. Stretchers are required not only by the intensive or critical care units of hospitals but also fields as different as Orthopaedics, Neurology, Rehabilitation centres etc.

Stretcher Accessories market Restraints

Medical equipment is very expensive and requires a lot of capital investment. An apprehension on the part of hospitals in the developing world because of the low return on investment (ROI) is a major issue for the stretcher and thus the stretcher accessories market. These countries, particularly in Sub-Saharan Africa, Latin America and Asia don’t have any legal protocols concerning proper handling of patients along with their handlers. Hence their healthcare systems are highly irregular, fragmented with lack of long term planning. Lack of awareness about how the accessories can minimize injuries for both patients and handlers also pose a major challenge for the stretcher accessories market. However, increased pressure from international organizations like WHO will spur these countries to adopt safer handling procedures in the future.

Stretcher Accessories market Key Regions

Europe is the largest market for patient handling equipment like stretchers and thus it would also be the largest stretcher accessory market. It is followed by North America which is the fastest growing. This is because of rising reports of non-communicable diseases which may lead to disability and strict government regulations mandating the procedure of handling patients. Asia Pacific is growing because of the rising population, increased investment in hospitals and healthcare by both the public and private sector and also government efforts to revamp their laws to make them more similar to those of developed countries. Companies competing in both the stretcher and stretcher accessories market would do well to focus their attention on this key region.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2255

Stretcher Accessories market Key Market Players

The main players in the stretcher accessories market are Stryker Corporation, Invacare Corporation, Invacare Corporation, ArjoHuntleigh (Getinge Group), Etac AB, Hill-Rom Holdings, Hill-Rom Holdings, Inc, Patterson Medical Holdings, Inc., Permobil AB, Stiegelmeyer & Co. GMBH, DJO Global and Sunrise Medical LLC.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain

Regional analysis includes:

North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain)
Eastern Europe (Poland, Russia)
Asia Pacific (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, N. Africa)

For critical insights, request for PDF Brochure https://www.futuremarketinsights.com/reports/brochure/rep-gb-2255

High frequency of lung cancer around the world is expected to spur the demand for the X-Ray Positioning Devices Market

X-Ray Positioning Devices Market Overview

X-Radiation (shortened to just X-Ray) is a kind of electromagnetic radiation, ranging from 0.01 to 10 nm and corresponding to frequencies between 30 petahertz to 30 exahertz. They are vital in the field of medical imaging since Wilhelm Rontgen’s discovery that they can be used to identify bone structure. They can be used to detect fractures, arthritis, blocked blood vessels, bone cancer, breast tumours, digestive problems, osteoporosis, tooth decay and various kinds of infections. There might be several instances where a radiologist is unable to perform an X-Ray without some sort of assistance. It could be if their patient has a knee injury or even if they have to immobilize a child so that it remains still. That is the sole purpose of the X-Ray positioning devices market. It includes various types of wedge, block and bolster sponge models which are usually made of foam or a special type of coated vinyl. These devices enable the patients to be comfortable and at ease while enabling the radiologist to take the X-ray quickly and efficiently.

X-Ray Positioning Devices market Drivers

X-Rays can be used to detect not only bone fractures but also various forms of cancers, tumours, digestive issues and infections. High frequency of lung cancer around the world due to smoking and/or Air pollution is expected to spur the demand for the X-Ray positioning devices market. New advancements in X-Ray technology also enable early detection of breast cancer, tumours or other infections. This encourages people to undergo an X-Ray to be able to start the treatment early (if required), thereby boosting the X-Ray positioning devices market as well.

X-Ray Positioning Devices market Restraints

As with all aspects of science, even the field of medicine is rapidly evolving. Point of care diagnostics to determine what is afflicting a patient has improved tremendously and provides far more insight to a doctor today with the help of modern day technology. This has made the need to undergo an X-Ray limited to only severe cases like head trauma (for an MRI or CT scan) or any other kind of serious issue. This also restrains the growth of the X-Ray positioning devices market. Some positioning devices like sandbags may contain ferromagnetic shavings or iron pellets which can damage MRI scanners or even injure the radiologist or patients in the worst case scenario. There are several studies which show that X-Ray equipment is all too often overused by medical centres. Insurance agencies have begun to refuse reimbursement in several cases which reduces the motivation for these clinics to invest in expensive X-Ray technology. This also reduces the chance of them requiring equipment sold in the X-Ray positioning devices market.

X-Ray Positioning Devices market Key Regions

North America is the largest X-Ray market at present and is thereby also the largest X-Ray positioning devices market. The demand in this region is from both hospitals as well as private clinics. In addition to this, the introduction of handheld X-ray devices has also spurred the demand for X-ray positioning devices. The patients requiring an X-Ray in this part of the world are usually (but not always) of an older age group due to the population structure. In Asia and Africa, there is a larger proportion of people below the age of 30 i.e. a younger demographic. Children in countries like China, India, Thailand or even African nations like Kenya, Nigeria and South Africa might frequently injure themselves while playing or even fracture a limb unfortunately. So manufactures would do well to market their products targeted at youth in the Asia Pacific or African X-Ray positioning devices market.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2282

X-Ray Positioning Devices market Key Market Players

Some manufacturers involved in the X-Ray positioning devices market are Z & Z medical, Cone instruments, Merry X-Ray, Universal Medical Inc, and Clear Image Devices.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain

Regional analysis includes:

North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain)
Eastern Europe (Poland, Russia)
Asia Pacific (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, N. Africa)

For any queries linked with the report, ask an analyst https://www.futuremarketinsights.com/ask-question/rep-gb-2282

Insulin Management System Market shows a promising market growth due high global prevalence and incidence, extensive research

Insulin Management System Market Overview

Frederick B and John M in 1923 were Nobel Prize awardee in Physiology or Medicine for discovery of Insulin. This serves a milestone in history of diabetes management as the death rate due to diabetes significantly reduced after its discovery. Insulin is a natural and most essential preprohormone produced by INS gene by islets of langerhans in pancreas by allowing body to take up glucose as energy source. Insulin prevents hyperglycemia and maintain blood sugar levels in co-ordination with glucagon. Diabetes is a most common health problem causing high blood sugar level resulting into excessive thirst and large amount of urine production. It causes secondary health associated problems such as diabetic ketoacidosis, hyperosmolar hyperglycemic states, and other serious complications (heart attack, stroke, kidney failure, leg amputation) leading to premature death. Diabetes is divided into 3 types i.e Type I diabetes, Type II diabetes and gestational diabetes. According to NCD CCS, insulin treatment is essential treatment for diabetes. FDA approved genetically engineered recombinant human Insulin and Insulin analogues are used in insulin management system.

Insulin Management System Market: Drivers and Restraints

It is being estimated by World Diabetes Foundation that there will be 438 million people with diabetes by year 2030 which interprets demand for insulin management system market or solutions to accompany escalating diabetes population. Insulin management system shows a promising market growth due high global prevalence and incidence, extensive research and advancement in technology for effective insulin delivery systems and support from government and health care centers in making insulin management systems available throughout globe. According to WHO since 1980, the global prevalence of diabetes in adult population has risen from 4.7% to 8.5%. While in past decade the prevalence of Diabetes in low and middle income countries is higher than in higher income countries. Also, according to research carried out in University of Florida the reason for the mortality of children with type I diabetes is lack of access to Insulin management systems due to its high price. Hence unavailability of cheaper or affordable insulin management system thus hinder its market growth while its availability would increase market size and demand in low and middle income countries.

Insulin Management System Market: Overview

Insulin treatment for Type II diabetes holds largest share due to its high prevalence and also availability of variety and advances in insulin management systems available to treat type II diabetes. Also in comparison to recombinant human Insulin there is greater share for insulin analogues due to its higher efficacy with fast and long lasting effects. Moreover in comparison to painful traditional methods of insulin administration by injections, use of inhaled insulins are expected to have larger share in insulin management system market. Inhaled insulins are easy to administer, fast acting and is eliminated from body in less time. Thus, Insulin that is affordable, easy to administer, readily available, fast acting with long lasting effect and quick elimination from body is expected to hold strong position in insulin management system market.

Insulin Management System Market: Regional Overview

Region wise, the global regions in Insulin Management System market is classified into, North America, Latin America, Western and Eastern Europe, Asia-Pacific (excluding Japan) and MEA (Brazil, Argentina, Nigeria, Saudi Arabia & Egypt). America dominates the global insulin management system market due to higher prevalence of diabetes, high income population and also due to significant patent protection for brands of biosimilar insulin. Europe holds second largest insulin management system market due to better disrtribution of network for key players in insulin management system market. While Asia Pacific and MEA is fastest growing due to adoption of various advancement in insulin management system. Initiatives taken by government in developing countries to provide better healthcare facilities and easy utilization of insulin management system plays a larger role in increasing market for insulin management systems.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2282

Insulin Management System Market: Key Players

Eli Lilly and Company, GlaxoSmithKline, Biocon, Sanofi Aventis, Julphar, Novo Nordisk, SemBioSys, and WOCKHARDT, Abbott India Ltd., USV Limited, Torrent Pharmaceuticals Ltd and Piramal Enterprises Limited are key players.

The report covers exhaustive analysis on:

Market Segments.
Market Dynamics.
Market Size.
Supply & Demand.
Current Trends/Issues/Challenges.
Competition & Companies involved.
Technology.
Value Chain.

Regional analysis includes

North America (U.S., Canada)
Latin America (Mexico, Brazil)
Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)

Request a Complete TOC of this Report with figures:
https://www.futuremarketinsights.com/toc/rep-gb-2282

The hospitals end user segment is expected to hold the highest market share in global Ventricle Assist Device Market

Ventricle Assist Device Market Overview

Heart failure is one of the most common cause of deaths worldwide, it is a condition when the heart cannot pump blood properly throughout the body. In most of the cases the left ventricle gets affected but sometimes the right ventricle gets affected and the heart cannot pump oxygen rich blood to the lungs. Ventricle assist devices are mechanical pumps which support the functioning of the heart in individuals who have weak heart. There are two types of heart failure one is diastolic heart failure and the other systolic heart failure. The major symptoms of heart failure are fatigue, irregular heart rhythm, blood pressure, heart valve functioning is affected, shortness of breath and fluid retention. Most of the above symptoms can be stabilized by the use of medication but in some cases ventricle assist devices have to be used depending upon the condition of the patient.

A ventricle assist device comprises of a small tubes transferring blood out of heart and into the pump, the heart pump is connected to a control unit, which monitors the functioning of the ventricle assist device. Recent research has shown that continuous flow ventricle assist devices are more effective as they reduce the hospitalization and improve survival rate of patients suffering from heart failure. The different types of ventricle assist devices available in the market, left ventricle support, right ventricle support and bi-ventricle support.

The ventricle assist devices are used for short-term period for individuals recovering from myocardial infraction or individuals recovering from cardiac surgery, and for long term use in individuals suffering from total heart failure. Ventricle devices are generally used as bridge to transplant, bridge to decision and bridge to recovery for an individual who is suffering from Class III & Class IV heart failure. Ventricle assist devices are generally implantable and transcutaneous depending on the individual heart condition.

Transcutaneous ventricle assist devices have the control unit installed outside the body and the pump placed inside the body whereas implantable ventricle assist devices are generally used for people waiting for heart transplant. Ventricle assist devices are generally categorized as Pulsatile and Non Pulsatile devices. Pulsatile devices were the first generation devices, whereas non pulsatile devices have a continuous flow as they allow the blood to move forward in a systemic circulation. In a non-pulsatile ventricle assist device all the parameters are displayed on the console or the control unit. Some of the common ventricle assist devices in the market are Thoratec VAD, Heart Mate and Jarvik 2000.Ventricle assist devices although have great benefits but some time they may give rise to certain complication like bleeding, infection, thrombosis, device malfunctioning and hemolysis.

When both the ventricle stop functioning or the entire heart fails, bi-ventricle assist devices are used and Total Artificial Heart is implanted. The rapid advancement in ventricle assist device technology has limited the TAH (Total Artificial Heart) development as majority of the heart failure can be controlled by using ventricle assist devices. At present the only TAH approved by the FDA is the Cardio West TAH by Syncardia System, which is a pneumatically powered dual chamber device.

Ventricle Assist Device Market: Drivers and Restraints

The global market for ventricle assist devices is expected to be driven by the advancement in technology and increasing prevalence of Class III & Class IV heart failure, increase in geriatric population, better reimbursement reforms are some factors anticipated to fuel growth of global ventricle assist devices market within the forecast period of 2016-2026. However the high cost certain complication which may arise after or during the implant and development of the total artificial heart can be the restraint for the growth of this market.

Ventricle Assist Device Market: Overview

Cost-effectiveness of ventricle assist devices and ongoing researches on improving quality of care for continence would create an attractive growth opportunities for the ventricle assist device market. The hospitals end user segment is expected to hold the highest market share in global market for ventricle assist devices.

A new generation of ventricle assist devices have been approved by the FDA which are more efficient in increasing the survival rate of individuals suffering from heart failure. These devices are much small smaller in size and much more efficient in restoring the functioning of the heart. These are centrifugal continuous flow pumps suspended through magnetic or hydrodynamic levitation in blood flow path, this levitation mechanism theoretically increases the device durability and reliability as there is no friction and heat generation component contact. The third generation left ventricle assist devices are more used in Europe.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2273

Ventricle Assist Device Market: Key Players

Some of the key players in global ventricle assist device market are SynCardia System Inc., St. Jude Medical, Berlin Heart, Heart Ware International, Jarvik Heart Inc. Abiomed, CardiacAssist Inc., and Reliant Heart Inc.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain

Regional analysis includes

North America (U.S., Canada)
Latin America (Mexico, Brazil)
Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)

For critical insights, request for PDF Brochure https://www.futuremarketinsights.com/reports/brochure/rep-gb-2273

Growing incidence of Pediatric Respiratory Syncytial Virus Infection among children is expected to increase demand for RSV infection treatment products

Pediatric Respiratory Syncytial Virus Infection Market Overview

Respiratory syncytial virus (RSV) is a common virus that causes respiratory infection. The virus infects lungs and respiratory passage. RSV infection is common among adults who experience symptoms like mild cold however in infants and older people the infection can be very serious. RSV is the most common cause of bronchiolitis and pneumonia among infants. RSV infection is limited to the respiratory tract. The virus inoculates in the lower respiratory tract and spreads into the respiratory system through cell to cell transfer in syncytia. RSV infection has very high incidence rate. According to the Centers for Disease Control and Prevention (CDC), almost all children get RSV infection by the age of 2 years. Moreover the Respiratory syncytial virus spreads very quickly through cough, sneeze and touching the infected surfaces which delivers the virus into the host body. The recovery period for RSV infection is around 1 to 2 weeks among infants, the virus still remains in the body and can spread easily to another person. Owing to high incidence rate, the market for pediatric syncytial virus infection is expected to witness robust growth over the forecast period.

Pediatric Respiratory Syncytial Virus Infection Market: Drivers and Restraints

Growing incidence of RSV among children is expected to increase demand for RSV infection treatment products. Rise in the birth rate is expected to propel demand for RSV treatment products over the forecast period. According to the United Nations, Department of Economic and Social Affairs, the global population is expected to reach 8.5 billion by 2030. This increase in the baby boomer population is expected to add to the patient pool of the RSP virus and thus in turn increase demand for RSV infection treatment over the forecast period. RSV infection can occur at any age however the infection rate among children varies as compared to adults. Among infants and children, nearly 25 out of every 40 children suffering from RSV infection, exhibit signs of bronchiolitis or pneumonia. Owing to severity of the infection the awareness among public regarding the RSV infection is growing which in turn is expected to boost demand for respiratory syncytial virus infection treatment. Increase in the risk of acquiring RSV among children is associated with the community settings like attending school, exposure to environmental pollutants etc. with changing social dynamic structure the incidence rate of RSV infection is expected to grow rapidly over the forecast period. However absence of definitive treatment, side effects and limited efficacy of the drugs available in the market and dependency in symptom based treatment in several cases is expected to hamper revenue growth of the pediatric respiratory syncytial virus infection market over the forecast period.

Pediatric Respiratory Syncytial Virus Infection Market: Overview

The global market for pediatric respiratory syncytial virus infection is expected to witness robust growth owing to increasing incidence rate of the RSV infection and growth in the birth rate.

Pediatric Respiratory Syncytial Virus Infection Market: Region – wise Outlook

Globally the pediatric respiratory syncytial virus infection market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Japan and Middle East and Africa (MEA). Globally RSV is responsible for nearly 18% of the total child deaths. North America and Western Europe are expected to be the leading markets in the global pediatric respiratory syncytial virus infection market. High awareness and easy available diagnostic tests are expected to boost demand for RSV infection treatment products in these regions. Japan and APEJ are expected to follow next in terms of demand for the treatment of pediatric respiratory syncytial virus infection market. Eastern Europe, Latin America and MEA markets are also expected to witness above average growth over the forecast period. Absence of population based studies in developing countries is a major challenge in assessment of RSV related infections in these countries.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2345

Pediatric Respiratory Syncytial Virus Infection Market: Participants

Some players in the global pediatric syncytial virus infection market are Ablynx NV, Aridis Pharmaceuticals, Inc., Artificial Cell Technologies, Inc. is conducting studies for development of vaccine against RSV. The company’s vaccines is into pre – clinical development and preparing for IND filing to conduct phase 1 trials. Astellas Pharma Inc. entered into strategic partnership with ClearPath Development company for building a vaccine portfolio for Respiratory Syncytial Virus, AstraZeneca is conducting observational studies of Respiratory Syncytial Virus Hospitalizations among U.S. infants. Bavarian Nordic., a biotechnology company is building a antibody based treatment against RSV, which is currently into phase 2 clinical trials.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types and technology.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Current Trends/Issues/Challenges
Competition & Companies involved
Value Chain

Regional analysis includes:

North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
Eastern Europe (Poland, Russia)
APEJ (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, N. Africa)

For any queries linked with the report, ask an analyst https://www.futuremarketinsights.com/ask-question/rep-gb-2345

The global market for Subcutaneous Implantable Defibrillator is expected to be driven by the key advantages of the subcutaneous implantable defibrillators

Subcutaneous Implantable Defibrillator Market Overview

Similar in functionality of the traditional Implantable Cardioverter Defibrillators (ICD), and the Transvenous Implantable Cardioverter Defibrillators (T-ICD), Subcutaneous Implantable Cardioverter Defibrillators (S-ICD’s), are used to treat patients with a history of life threatening Arrhythmias (ventricular tachycardia or fibrillation). Unlike the conventional Implantable Defibrillators which are implanted intravascular, the Subcutaneous Implantable Defibrillators are inserted subcutaneously under the skin, and uses a subcutaneous electrode placed near the heart, rather than into the heart as in case of conventional Implantable Defibrillators. A Subcutaneous Implantable Defibrillator consists of a small titanium case which contains battery, a subcutaneous electrode, and accessories such as insertion tool etc. If there is any abnormality in the patient’s heartbeat, the subcutaneous implantable defibrillator sends and electrical impulse to restore normalcy in the heart rhythm, followed by pacing therapy in form of post shock bradycardia, if needed. Implantable defibrillators are useful in saving patients’ lives with known history of ventricular tachycardia and arrhythmias. The US-FDA recently approved the use of subcutaneous implantable defibrillators in 2012, following proven efficiency after clinical studies. According to a study published in the New England Journal of Medicine (2010), demonstrated a concept of the subcutaneous implantable defibrillators. Any person with a history of a congenital heart disease, heart attack, sudden cardiac arrest, or ventricular arrhythmia, may need a subcutaneous implantable defibrillator.

Subcutaneous Implantable Defibrillator Market: Drivers and Restraints

The global market for Subcutaneous Implantable Defibrillator is expected to be driven by the key advantages of the subcutaneous implantable defibrillators over the conventional Implantable defibrillators, such as the placement of electrode near the heart, rather than on the heart in case of conventional defibrillators which reduces risks, and longer shelf life, and ease of insertion and removal of the subcutaneous defibrillators. Also Increasing incidences of cardiovascular diseases, increasing geriatric population around the world, changing lifestyle, increased smoking, rising prevalence of strokes, and increasing technological advancements in the medical devices industry are some of the factors responsible for the growth of the subcutaneous implantable defibrillators market during the forecast period of 2016-2024. However patients with a history of symptomatic ventricular bradycardia, or patients with a heart failure for whom resynchronization is advised, cannot use subcutaneous implantable defibrillators as the device provides a post-shock pacing therapy whenever needed, and this can lead to complications in patients with bradycardia. Another restraint for the growth of the subcutaneous implantable defibrillators market is that the clinical efficiency of the subcutaneous implantable defibrillators in general population is still not proved.

Subcutaneous Implantable Defibrillator Market: Overview

Ventricular Tachycardia in the indications segment is expected to dominate the global subcutaneous implantable defibrillators market during the forecast period, due to changing lifestyles leading to increasing cases of cardiac disorders, and increased smoking prevalence. In the end users segment, hospitals is expected to dominate the global subcutaneous implantable defibrillators market, due to increasing cardiac surgeries, improving hospitals infrastructure and increased adoption of sophisticated and advanced technologies by hospitals.

Subcutaneous Implantable Defibrillator Market: Regional Overview

Region wise, the global subcutaneous implantable defibrillator market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America dominated the global market for implantable defibrillators, due to good reimbursement policies for surgical procedures, US-FDA approval and increased demand for subcutaneous implantable defibrillators. Increasing incidences of cardiovascular diseases owing to changing lifestyle and increasing geriatric population in the Asia Pacific region is expected to boost the market growth in APEJ region.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2436

Subcutaneous Implantable Defibrillator Market: Key Players

Some of the key players in global Implantable Defibrillator market include Boston Scientific Corporation, LivaNova PLC Company, Imricor Medical Systems, Inc., MicroPort Scientific Corporation, Mayo Clinic US, Medtronic plc, MRI Interventions, Inc., and St. Jude Medical, Inc.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain

Regional analysis includes

North America (U.S., Canada)
Latin America (Mexico, Brazil)
Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)

Report Highlights:

Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint

Request a Complete TOC of this Report with figures:
https://www.futuremarketinsights.com/toc/rep-gb-2436

Aquaculture Therapeutics Market to Grow at Robust CAGR by 2026

Aquaculture Therapeutics Market Overview

The Farming or the culturing of aquatic animals like the fishes, algae, mollusks, crustaceans, aquatic plants and other aquatic organisms in different types of water is termed as Aquaculture. The cultivation process involves nurturing of these aquatic organism in the controlled condition either in fresh or in salt water. Later on these aquatic organisms are then harvested to be served as the source of nutrition or to be used for many other purposes. The aquatic animals are very sensitive and are prone to various epidemic diseases. Other factors affecting the aquatic cultured animals are Pathogens (e.g. bacteria, viruses, fungi and parasites) exist in all natural water bodies. At the same time crowded culture environment makes the causes high risk for infection and makes the fishes nervous. Crowding also results in fish knocking eventually leading to surface wounds which is a cause for inaction. These can be cured using several FDA approved antibiotics and other medicines. Apart from diseases medicines are used to improve the wellbeing of the fishes in the aquaculture. The list of drugs includes chorionic gonadotropin, formalin solution, florfenicol, oxytetracycline, tricaine methane sulfonate, hydrogen peroxide, sulfadimethoxine/ormetoprim combination, acetic acid, calcium chloride, calcium oxide, carbon dioxide gas, fuller’s earth, garlic (whole form), ice, magnesium sulfate, papain, potassium chloride, povidone iodine, sodium bicarbonate, sodium chloride, sodium sulfite, thiamine hydrochloride, urea and tannic acid. The above mentioned drugs take care of the aquatic animals fighting with several diseases which are not only harmful to the aquatic animals but are also harmful to the consumer. There are two different categories of diseases which affect the aquatic population viz. diseases due to pathogens which are indigenous to the local environment and exotic pathogens.

Aquaculture Therapeutics Market: Drivers and Restraints

A lot of advances are taking place in the aquaculture therapeutics as there are several diseases which are affecting the animals cultured in the aquaculture. There are several diseases which are driving the aquaculture therapeutics market. Mostly the diseases are dependent on hygiene conditions which are to be maintained. Advances in aquaculture therapeutics, and growing demand for the more effective aquaculture therapeutic drugs are the factors expected to drive the growth of aquaculture therapeutics market. More over the demand for aquaculture is growing day by day due to the decreasing number of the oceanic fishes and increasing consumption of the fishes at a global level.

Aquaculture therapeutics market: Overview

Despite the long tradition of practicing aquaculture in several countries it is still a growing and a business with great scope. The requirement of aquaculture therapeutics is increasing day by day as more and more countries have stared adopting aquaculture which is cheaper source of protein. As the fishes or the animals are consumed by the human FDA has set up certain regulatory guidelines for the drugs to be administered to the fishes in aquaculture. They are categorized as conditionally approved animal drugs and indexed animal drugs. Depending upon environmental and diseased conditions these drugs are used in the aquatic fishes.

Aquaculture therapeutics market: Regional Overview

Region wise, the global Aquaculture therapeutics market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. China is the leading in the aquaculture market which contributes around 61% of the global aquaculture market which is followed by Indonesia and India.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2463

Aquaculture therapeutics market: Key Players

Some of the key players in global Aquaculture therapeutics market are TunaTech GmbH, ViAqua Therapeutics Ltd, Alpharma, Inc.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, type of product and applications.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain

Regional analysis includes

North America (U.S., Canada)
Latin America (Mexico, Brazil)
Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)

For critical insights, request for PDF Brochure https://www.futuremarketinsights.com/reports/brochure/rep-gb-2463

Equine Veterinary Therapeutics Market is growing with the increasing focus on return over investment are growing the market

Equine Veterinary Therapeutics Market Overview

Equine veterinary therapeutics is the branch of equine healthcare that deals with the prevention and treatment of several diseases. Equine veterinary therapeutics includes drugs that is used for the treatment of equine diseases, vaccines that used for the prevention of several disease and prevention of equine from various pathological conditions and additives that is used for the overall maintenance of heath and providing with sufficient minerals for a healthy life. The overall veterinary therapeutic market is growing in the past few years due to the increasing awareness towards veterinary healthcare. Increasing importance among human life for horses is an underpinning factor for the growth of equine veterinary therapeutic market. The increasing zoonotic diseases affecting horses are expected to fuel the market of equine veterinary therapeutic market. The increasing awareness towards prevention and well-being of livestock and companion animals is expected to fuel the market of equine veterinary therapeutics market. The equines are majorly consisting of horse racing and betting, leisure and competitive riding. Equines are also used in equine-facilitated therapy which includes therapy for specific motor, sensory and social responses. Therapy with equines is used to promote occupational, emotional and physical growth in patients with several mental disorders. These therapies include therapeutic horseback riding and hippotherapy. Equines healthcare includes equine therapeutics market and equine vaccines market. There are many companies and government initiatives taken to make horse owners and trainers to understand and improve the management of the requirements of their horse. This is one of the reasons for the growth of equine veterinary therapeutics market. The policies includes providing owners with articles written by veterinarians and nutritionists about the requirements and amount of nutrition intakes for the better well-being of equine. There are many research performed for better function of equine muscles using different stimulation process. Functional Electrical Stimulation (FES) is used now for injury healing and enhancement of healing.Equine Veterinary Therapeutics Market: Drivers and Restraints

Equine veterinary therapeutics market is growing with the increasing focus on return over investment are growing the market. The growing investments on international racing competition from different geographical regions are expected to fuel the market. The increasing animal healthcare base, growing economy, increasing trend towards pet ownerships is also expected to increase the equine veterinary therapeutic market. The increasing pet population and introduction of new products is expected to increase the market of equine therapeutics. The stringent regulations by government are expected to act as a restraint to the market.

Equine Veterinary Therapeutics Market: Overview

Drug is the major segment of the market that includes anti-inflammatory, anti- infective, parasitives and others. The other two segment includes vaccines and feed additives. The global vaccine segment is further divided into Recombinant vaccines, Inactivated Vaccines, Live attenuated vaccines and others. The rising awareness among population about different vaccines for equine is expected to boost the market of vaccine segment. The other segment includes medicated feed additives that includes vitamins, antibiotics, amino acids, enzymes and others. The increasing demand for feed additives and affordability is expected to rise the market of this segment. Amino acids are used for better protein production and quality.

Equine Veterinary Therapeutics Market: Regional Overview

Region wise, the global equine veterinary therapeutics market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is expected to lead the market due to better economic condition, better government initiatives and more business investments. Latin America market is expected to hold second largest market share followed by Europe due to increasing trend towards racing competitions and awareness among population.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2500

Market: Key Players

Some of the players in equine veterinary therapeutics market includes: Merck animal heath, Affymetrix, Elanco animal heath,Zoetis (Pfizer Animal Health), Equine Health U.K.and others.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Value Chain

Regional analysis includes

North America (U.S., Canada)
Latin America (Mexico, Brazil)
Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)

For any queries linked with the report, ask an analyst https://www.futuremarketinsights.com/ask-question/rep-gb-2500

Seasonal Influenza Vaccines Therapeutics Market Insights and Forecast by 2026

Seasonal Influenza Vaccines Therapeutics Market Overview

Influenza vaccine typically known as flu shot and is used for protection against influenza virus. An influenza vaccine is a combination of three viruses types namely, influenza type A with H3N2 virus strain, influenza type A with H1N1 virus strain and influenza type B virus strain. Influenza is a contagious respiratory illness caused by influenza viruses, which may cause mild to severe illness. Severity of the illness might land up to hospitalization or death. The risk of the serious flu complication is more in the age group such as older people, young children, and people with certain health conditions. It should be a habit to get vaccinated every year against this virus, as part of the best practice to avoid getting infected. The categorization of this influenza virus is done into the mentioned categories, influenza A (H1N1) virus, an influenza A (H3N2) virus, and one or two influenza B viruses, depending on the flu vaccine. Patients show symptoms like chills, cough, sore throat, running nose, body aches, headache, fatigue, some cases people may have vomiting and diarrhea, this is commonly seen in children than adults. This flu is mostly spread through droplets from infected people, flu cough, sneeze or talks. A person’s eyes, mouth and nose are the entry channels through which the virus enters. Infection can be spread by most healthy adults beginning 1 day before symptoms develop and up to 5 to 7 days after becoming sick. Once a person is symptomatic to the virus until onset, the span is 1 to 4 days, with an average of 2 days. For children and people with weak immune system; they might infect others even for a longer period of time. The complication of virus may include bacterial pneumonia, ear infections, sinus infections, dehydration, and worsening of chronic medical conditions, such as congestive heart failure, asthma, or diabetes. Chronic medical condition may occur such as congestive heart failure, asthma, or diabetes.

Seasonal Influenza Vaccines Therapeutics Market: Drivers and Restraints

The key drivers for seasonal influenza vaccines therapeutic market is increasing disease awareness on influenza caused by threat of pandemic influenza, wider vaccination coverage and rising government support for immunization against seasonal influenza. Also, the major market players have a great pipeline products, thus making a strong product portfolio.

The major restrains of this market are variable demand, limited production capacity, a high level of required investment, and strict regulations present barriers to new entrants.

Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies. The categorization of this influenza virus is done into the mentioned categories, influenza A (H3N2) virus, an influenza A (H3N2) virus, and one or two influenza B viruses, depending on the flu vaccine.

The third major segmentation category is the geographical segmentation. This would depend upon the geographical market which is most flouring for the given vaccine market.

Seasonal Influenza Vaccines Therapeutics Market: Overview

According to the patient population, preventive healthcare is better compared to curative healthcare; which had led to increased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. The seasonal influenza vaccine market in the APAC region is a fast growing market. This is due to increased vaccination coverage against seasonal influenza in the region. It is forecasted that the market can grow at a double digit of Compounded Annual Growth Rate (CAGR) of 9% during the period 2011–2018 from $1,015m in 2011 to $1,879m by 2018.

The R&D pipeline with phase II and phase III vaccines for the seasonal influenza is moderately strong with approximately 50% of the pipeline in the mentioned phases. The big shot vaccine manufacturers are focused upon acquiring new technologies and strengthening their presence in the market by collaborating with or acquiring small and medium sized biotech companies that have strong vaccine candidates in their pipeline. Various companies have their on-going activities for newer technological development and also for novel vaccines that can help the market to revolutionize.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2498

Seasonal Influenza Vaccines Therapeutics Market: Key Players

Top six players of influenza vaccine manufacturers occupy more than 75% of the total influenza vaccine market. GSK’s seasonal influenza vaccine brands like Fluarix & Flulava were one of the leading players in the market in 2010. The key players in this market include GlaxoSmithKline, Novartis, CSL, MedImmune, Sanofi-Pasteur, Solvay, Sinovac Biotech and Hualun Biologicals. Some of the other market players are ID Biomedical Corp. of Quebec (distributed by GlaxoSmithKline), Seqirus, Protein Sciences, MedImmune, etc.

The study is a source of reliable data on:

Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis

The regional analysis covers:

North America (U.S. and Canada)
Latin America (Mexico, Brazil, and others)
Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Benelux, Poland, Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia and New Zealand)
Middle East and Africa (GCC, Southern Africa, North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a completequalitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

Request a Complete TOC of this Report with figures:
https://www.futuremarketinsights.com/toc/rep-gb-2498